Human Sirtuin Regulators: The “Success” Stories

Alyson M. Curry¹, Dawanna S. White¹, Dickson Donu¹ and Yana Cen¹,²*

¹ Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, United States, ² Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, VA, United States

The human sirtuins are a group of NAD⁺-dependent protein deacylases. They “erase” acyl modifications from lysine residues in various cellular targets including histones, transcription factors, and metabolic enzymes. Through these far-reaching activities, sirtuins regulate a diverse array of biological processes ranging from gene transcription to energy metabolism. Human sirtuins have been intensely pursued by both academia and industry as therapeutic targets for a broad spectrum of diseases such as cancer, neurodegenerative diseases, and metabolic disorders. The last two decades have witnessed a flood of small molecule sirtuin regulators. However, there remain relatively few compounds targeting human sirtuins in clinical development. This reflects the inherent issues concerning the development of isoform-selective and potent molecules with good drug-like properties. In this article, small molecule sirtuin regulators that have advanced into clinical trials will be discussed in details as “successful” examples for future drug development. Special attention is given to the discovery of these compounds, the mechanism of action, pharmacokinetics analysis, formulation, as well as the clinical outcomes observed in the trials.

Keywords: sirtuin, inhibitor, activator, clinical trial, drug development

INTRODUCTION

Initially, sirtuins were classified as epigenetic “eraser” enzymes dedicated for the removal of acetyl groups from histone N-terminal lysine residues (Blander and Guarente, 2004; Trapp and Jung, 2006). The deacetylation of histones causes chromatin condensation, which is closely associated with transcription silencing (Shahbazian and Grunstein, 2007). Unlike the Zn²⁺-dependent histone

Abbreviations: Aβ, Amyloid beta; AD, Alzheimer’s disease; ADME, Absorption, distribution, metabolism, excretion; AE, Adverse effect; AMPK, AMP-activated protein kinase; BBR, Blood-brain barrier; BDNF, Brain-derived neurotrophic factor; Cmax, Maximum concentration of a drug in the intended organ/tissue after administration; CML, Chronic myeloid leukemia; COPD, Chronic obstructive pulmonary disease; COX, Cyclooxygenase; CRC, Colorectal cancer; EC₅₀, Concentration at which the enzyme activity is increased by 50%; FOXO, Forkhead box transcription factor; GI, gastrointestinal; HD, Huntington’s disease; HDACS, Histone deacetylases; HDL, High density lipoprotein; HDX-MS, Hydrogen deuterium exchange mass spectrometry; HTS, High-throughput screening; IC₅₀, Half-maximal inhibitory concentration; IGFBP, Insulin-like growth factor binding protein; IGF-I, Insulin-like growth factor I; IHD, Ischemic heart disease; ITC, Isothermal colorimetry; Km, Michaelis-Menten constant; LDL, Low density lipoprotein; mHTT, mutant Huntington gene; MI/R, Myocardial/ischemia-reperfusion; MOA, Mechanism of action; NAD, Nicotinamide adenine dinucleotide; NAFLD, Non-alcoholic fatty liver disease; NF-kB, Nuclear factor κB; NFTs, Neurofibrillary tangles; NMR, Nuclear magnetic resonance; PD, Pharmacodynamic; PGC, Peroxisome proliferator-activated receptor-gamma coactivator; PK, Pharmacokinetic; PTEN, Phosphatase and tensin homolog; RSV, Resveratrol; SAR, Structure-activity relationship; SBD, STAC binding domain; SPR, Surface plasmon resonance; STACs, Sirtuin-activating compounds; SULTs, Uridine-5′-diphosphoglucuronosyltransferases; TAMRA, Tetramethylrhodamine; T2D, Type 2 diabetes mellitus; UC, Ulcerative colitis; UGTs, Uridine-5′-diphosphoglucuronosyltransferases.
deacetylases (HDACs), sirtuins carry out the chemical modifications in an NAD\(^+\)-dependent fashion (Imai et al., 2000; Landry et al., 2000). Growing evidence suggests that sirtuins not only act on histone proteins, but also have other cellular targets such as transcription factors and metabolic enzymes (Sauve et al., 2006; Kosciuk et al., 2019). Furthermore, diverse catalytic activities have been uncovered for sirtuins, including, but not limited to, depropionylation, deubiquitylation, desuccinylation, and de-fatty acylation (Du et al., 2011; Feldman et al., 2013; Jiang et al., 2013; Anderson et al., 2017). These pleiotropic enzymatic activities give sirtuins their far-reaching functions in maintaining genome integrity, regulating metabolism homeostasis, and promoting organismal longevity (Guarente and Picard, 2005; Cen et al., 2011; Watroba et al., 2017).

The human sirtuins, SIRT1-SIRT7, have been intensively investigated for their enzymatic activities and biological functions. There are numerous wonderful review articles highlighting the significance of these enzymes in regulating normal physiology and pathophysiology (Chang and Guarente, 2014; Herskovits and Guarente, 2014; Kumar and Lombard, 2018; Chang et al., 2020; Jaiswal et al., 2021). For example, overexpression of SIRT1 has been observed to increase carcinogenesis in prostate and thyroid tumors in mice with a deficiency of tumor suppressor PTEN (phosphatase and tensin homolog) (Herranz et al., 2013). SIRT1 also plays an important role in the development of drug resistance in chronic myeloid leukemia (CML) cells (Wang et al., 2013). It has been shown to activate error-prone DNA repair which can lead to increased incidence of genetic mutations (Wang et al., 2013). Thus, a SIRT1 inhibitor would be beneficial in combination with established chemotherapeutics to reduce drug resistance. Sirtuin activators can also play an important role in disease modulation. SIRT1 is considered to have a neuroprotective role in the brain, as it helps to regulate apoptosis and BDNF (brain-derived neurotrophic factor) expression (Luo et al., 2001; Zocchi and Sassone-Corsi, 2012). Activation of SIRT1 may be beneficial for the treatment of Alzheimer’s disease (AD), in which SIRT1 levels are typically reduced (Lutz et al., 2014). AD is characterized by the presence of amyloid plaques containing amyloid beta (A\(\beta\)) and neurofibrillary tangles (NFTs) containing hyperphosphorylated tau (Ittner and Götz, 2011). SIRT1 overexpression was shown to increase \(\alpha\)-secretase activity, thus reducing the formation of A\(\beta\) (Endres and Fahrenholz, 2012). SIRT1 also prevents AD pathology through the deacetylation of tau (Min et al., 2010). Tau acetylation inhibits the degradation of tau and is detected in early stages of diseases with abnormal tau accumulation (Min et al., 2010). Therefore, SIRT1 serves as a possible therapeutic target for the treatment of AD.

Naturally, the development of small molecule regulators targeting human sirtuins has become a hot topic of research. Despite all the efforts over the last few decades, the success stories were scarce. Many small molecule sirtuin inhibitors and activators can only be called “chemical probes” at the present time due to the lack of isoform selectivity, moderate potency, limited bioavailability, and poor pharmacokinetic (PK) and pharmacodynamic (PD) profiles. There is a clear gap between the pre-clinical probe discovery and clinical drug candidate development. There is also a gap in the amount of research effort put into studying the various sirtuin isoforms. SIRT1 is by far the most studied isoform, with over 11,000 articles indexed in PubMed. In comparison, the other two most studied isoforms, SIRT2 and SIRT3, together have only around 3,700 articles. This disparity in research translates to fewer small molecule modulators targeting the other isoforms. Thus, the modulators that have entered clinical trials are primarily focused on SIRT1.

In this review, we will “tell the tales” of several human sirtuin regulators that have advanced into clinical investigation for the treatment of various diseases. The focus of the discussions will be the discovery of these compounds, their mechanism of action (MOA), and the rationale and outcome of the clinical trials. Although we brand these compounds as the “success” stories, they are not without controversy or limitation. On the flip side, the lessons we learn from these examples may help guide the design and development of the next generation of sirtuin regulators as therapeutic candidates.

For the benefit of the general audience, we would like to briefly discuss the basic theories behind the development of small molecule drug candidates toward clinical trials. The candidate compounds are normally small molecules, either natural products or synthetic compounds, with desired biological activity toward target proteins or enzymes in the in vitro setting. These candidates are the results of rounds of optimization for improved potency, selectivity, and solubility. For example, Lipinski’s rule of five (Ro5) has been the golden standard to prioritize the drug-like properties of orally active compounds (Lipinski et al., 2001). The “druggability” of the candidates will then be analyzed through ADME (absorption, distribution, metabolism and excretion) studies. These studies will assess the bioavailability, distribution, stability, and elimination of the candidate compounds. In the following sections, \(C_{\text{max}}\) of certain sirtuin modulators will be discussed. This critical parameter in ADME analysis describes the maximum concentration of a candidate compound in targeted tissue/organ after administration. The results from ADME studies will guide the further optimization of the candidate molecules. The best dosage, administration route, and formulation need to be evaluated as well. The formulations of resveratrol (RSV) will be discussed in detail in the next section. The active ingredient, RSV, has been combined with variety of substances to improve its bioavailability.

**RESVERATROL AND RELATED SRT COMPOUNDS**

**Resveratrol**

In the 1980s, epidemiologists observed that developed countries with increased wine consumption had decreased deaths due to ischemic heart disease (IHD) (St Leger et al., 1979). This later came to be known as the “French Paradox” because of the lowered IHD mortality rates in France despite having no difference in saturated fat intake or blood cholesterol levels (Burr, 1995). In Bertelli et al. (1995) implicated resveratrol (RSV, Figure 1) as the mediator of the cardioprotective effects of wine, thus spurring interest in the molecule as a potential therapeutic. The
association between RSV and SIRT1 was discovered in 2003 by high-throughput screening (HTS) utilizing a Fluor de Lys deacetylation assay on a library of plant-derived polyphenols (Howitz et al., 2003). Howitz et al. (2003) found that RSV activated SIRT1 deacetylase activity by decreasing the $K_M$ for both NAD$^+$ and the acetylated peptide. In addition to its effects on SIRT1, RSV was also shown to act on a wide range of enzymes, including COX-1, cAMP degrading phosphodiesterases, and nuclear factor-$\kappa$B (NF-$\kappa$B) (Jang et al., 1997; Manna et al., 2000; Pezzuto, 2011; Park et al., 2012). Consequently, there is debate whether the observed effects of RSV treatment are due to SIRT1 activation. For example, RSV has been shown to promote autophagy and many have attributed this effect to SIRT1 activation (Morselli et al., 2010; Wu et al., 2011). But this assertion was disputed by a study that observed the direct inhibition of mTOR, an inhibitor of autophagy, by RSV (Park et al., 2016). Despite the promiscuous nature of RSV, a study by Price et al. (2012) found that the presence of SIRT1 was necessary for RSV-mediated mitochondrial biogenesis and AMPK activation.

After the discovery of RSV as a SIRT1 activator, the validity of the study and its use of the Fluor de Lys assay was disputed. As the assay uses a synthetic peptide substrate that contains a fluorophore, some argued that it was not physiologically relevant and could produce false positives. Kaeberlein et al. (2005) were able to replicate the activation of SIRT1 by RSV, but only when the fluorescent moiety was present on the peptide substrates. Other studies confirmed that the fluorophore was necessary for RSV-promoted activation of SIRT1 (Borra et al., 2005; Beher et al., 2009; Pacholec et al., 2010). In one such study, Pacholec et al. (2010) used NMR, SPR, and ITC to prove that the sirtuin-activating compounds (STACs) were directly interacting with the fluorophore attached to the peptide, even in the absence of SIRT1. Altogether, the contradictory results called into question the reliability of the fluorometric assay and raised serious doubts concerning RSV’s mechanism of action and its ability to bind to and activate SIRT1 (Schmidt, 2010).

In response to the controversy, scientists at Sirtris, a company established after the initial discovery of SIRT1 activation by RSV, provided an explanation for the importance of the fluorescent moiety. Dai et al. (2010) observed the formation of STAC-substrate complexes, but found no correlation between the potency of a STAC and its affinity for the fluorescent TAMRA group. They further found that the ability of a STAC to activate SIRT1 was dependent on the substrate structure and were able to induce RSV-activation of SIRT1 using substrates composed of
natural amino acids (Dai et al., 2010). This finding was also seen by Lakshminarasimhan et al. (2013) in which they observed RSV-activation of SIRT1 after replacing the fluorophore with a large, hydrophobic residue. Hubbard et al. (2013) further found that the fluorophore or its hydrophobic replacement has a positional requirement and were able to show that hydrophobic motifs within PGC-1α and FOXO3a could facilitate SIRT1 activation. Additionally, they also determined that the conserved residue Glu230 was critical for RSV activation and found that the benefits of RSV were attenuated when SIRT1 Glu230 mutants were expressed in myoblasts (Hubbard et al., 2013).

After enough evidence was presented confirming an interaction between RSV and SIRT1, the focus shifted to identifying how RSV interacts with SIRT1. When the association between RSV and SIRT1 was first reported, RSV was categorized as an allosteric modulator of the “K system” type (Monod et al., 1965; Howitz et al., 2003). For “K system” modulators, the $K_M$ value is affected while the $V_{max}$ remains the same. Identifying the region of SIRT1 where RSV binds was the first step in characterizing the interaction. SIRT1 is comprised of three major structured regions: an N-terminal domain (183–229), a catalytic domain (229–516), and a C-terminal regulatory region (641–665) (Davenport et al., 2014). The apo enzyme undergoes a conformational change following the binding of NAD$^+$ into a “closed” form that traps the substrate (Yuan and Marmorstein, 2012; Davenport et al., 2014). Using hydrogen deuterium exchange mass spectrometry (HDX-MS), Dai et al. (2015) were able to investigate the STAC binding domain (SBD) and determine that residues 183–229 were necessary for STAC activation of SIRT1. A crystal structure of a SIRT1/FdL-peptide/RSV complex by Cao et al. (2015) indicated the binding of 3 RSV molecules for each SIRT1. Two of the RSV molecules form hydrogen bonds with the peptide and the SBD, thus bringing the two domains together in a “closed” conformation with improved substrate binding (Cao et al., 2015; Dai et al., 2018). The perspective of RSV acting as a stabilizing force between the substrate and SIRT1 has also been observed in a computational study in which RSV restored binding of “loose-binding” substrates (Hou et al., 2016).

Bioavailability is the primary obstacle in the development of RSV as a therapy. In human trials, Walle et al. (2004) observed that RSV had an absorption of ~70%, but were unable to detect unmodified RSV 30 min after administration. After absorption, RSV is rapidly metabolized in the liver where it is conjugated to either sulfate or glucuronate (Springer and Moco, 2019). The RSV conjugates are produced by sulfotransferases (SULTs) and uridine-5’-diphospho-glucuronosyltransferases (UGTs) (Springer and Moco, 2019). Both SULTs and UGTs have genetic polymorphisms that can affect their ability to metabolize drugs, and thus can lead to high variability in levels of unmodified RSV between individuals (Ung and Nagar, 2007; Mehboob et al., 2017). The sulfate-conjugated metabolites, which are the primary conjugated form of RSV, were shown to have similar actions to RSV. Calamini et al. (2010) found that the sulfate conjugate of RSV was able to inhibit COX-1 and COX-2, and could activate SIRT1 only in the presence of a Fluor de Lys substrate. As the level of the conjugated forms of RSV surpass that of free RSV, it remains unclear which molecule is responsible for the experimentally observed effects of RSV supplementation.

Development of novel formulations of RSV emerged as its bioavailability became a prominent issue. One approach was to inhibit the enzymes responsible for conjugating RSV. Co-administration of RSV with quercetin was shown to decrease the formation of RSV-sulfate conjugates through the inhibition of SULT1A1, the major SULT isoform expressed in the liver and kidneys (De Santi et al., 2000). Multiple studies have observed the synergistic effect between RSV and quercetin from reducing adipose tissue weight following a high fat diet (Arias et al., 2016) to inhibiting the development of prostate cancer in a mouse model (Singh and Ahmad, 2015). In a similar fashion, Reen et al. (1993) combined RSV with piperine, an alkaloid previously shown to diminish the activity of UGTs in the intestines of rats. The study found that the addition of piperine to RSV resulted in a more than 1000% increase in the maximum serum concentration of RSV (Johnson et al., 2011). Despite the promising results seen in animal models, outcomes from human trials in healthy subjects were ambiguous (Table 1). Two trials co-administering RSV and quercetin found no improvement in RSV pharmacokinetics (la Porte et al., 2010; Huhn et al., 2018). Piperine supplementation was found to be useful in improving RSV bioavailability in one study examining cerebral blood flow (Wightman et al., 2014), but had no beneficial effect on serum levels of RSV in another study (Bailey et al., 2021).

Other groups tried to solve the bioavailability issue by focusing on the drug delivery method. The Fioretti lab developed a novel formulation of RSV as a solid dispersion on Magnesium dihydroxide microparticles. In their early studies, they found that the new formulation (later termed Revifast) was three times more soluble than the unmodified RSV and had enhanced bioavailability in rabbits (Spogli et al., 2018). In human trials, Revifast displayed an earlier peak in RSV as well as a twofold increase in free-RSV levels in plasma (Iannitti et al., 2020). Another method used to increase bioavailability of RSV is micronization. Sirtris developed SRT501, in which they reduced the particle size below 5 μm in order to improve solubility by increasing the surface area of RSV. In an early clinical trial, SRT501 was well tolerated in colorectal cancer (CRC) patients and had an improved $C_{max}$ compared to conventional RSV (Howells et al., 2011). Following that success, SRT501 was used as a treatment for patients with refractory or relapsed multiple myeloma. The clinical trial was terminated early due to severe side effects including nephrotoxicity (Popat et al., 2013). SRT501 was later discontinued for development as the company focused on other SIRT1-activating drug candidates.

RSV has been extensively studied in clinical trials. In the NIH clinical trial registry, over 150 trials using RSV are in various stages of completion. The trials concerned with sirtuin activation and the resulting therapeutic effects have been compiled in Tables 2–9. When summarizing the clinical outcomes of RSV (Figure 2), the issues with RSV are apparent. For most disease states RSV had a neutral effect, suggesting that the bioavailability issues are a major obstacle. Most of the trials in which RSV had a positive effect had higher dosages, typically over 500 mg/day, and the more recent trials are trending toward higher dosages as
TABLE 1 | Clinical trials examining pharmacokinetics of novel resveratrol formulations and administrations.

| Formulation/admnistration | Description | Outcomes | References |
|---------------------------|-------------|----------|------------|
| Revifast                  | Solid dispersion of RSV on Magnesium dihydroxide | Revifast had C_{max} threefold higher than RSV and an earlier peak in RSV | Iannitti et al., 2020 |
| SRT501                    | Micronized RSV; 5,000 mg/day | SRT501 had a 3.6-fold increase in plasma RSV levels compared to non-micronized RSV | Howells et al., 2011 |
| JOTROL                    | Micellar emulsion | Recruiting | NCT04668274 |
| With food                 | High fat meal | RSV taken with food had delayed absorption, but the amount of absorption was not affected | Vaz-da-Silva et al., 2008 |
| RSV/Piperine              | 2,500 mg RSV + 0/5/25 mg Piperine | No significant change in pharmacokinetics was seen | Bailey et al., 2021 |
| RSV/Quercetin             | 2,000 mg RSV + 500 mg Quercetin | No significant change in RSV exposure | la Porte et al., 2010 |

TABLE 2 | Resveratrol clinical trials for cancer.

| Condition            | Phase | Subjects | Dose | Outcome | References |
|----------------------|-------|----------|------|---------|------------|
| Cancer prevention    | I     | 40       | 500, 1,000, 2,500, 5,000 mg/day 29 day | RSV safe, but higher doses had GI side effects; RSV treatment caused decrease in IGF-I and IGFBP-3 levels | Brown et al., 2010 |
| CRC                  | I     | 20       | 5,000, 1,000 mg/day 8 day | RSV treatment reduced tumor cell proliferation by 5% | Patel et al., 2010 |
| Cancer prevention    | I     | 42       | 1,000 mg/day | RSV affected enzymes involved in carcinogen activation and detoxification (CYP3A4, CYP2D6, CYP2C9) | Chow et al., 2010 |
| Multiple Myeloma     | II    | 24       | 5,000 mg | Terminated early-severe renal side effects | Popat et al., 2013 |

TABLE 3 | Resveratrol clinical trials for cardiovascular diseases.

| Condition                      | Phase | Subjects | Dose | Outcome | References |
|--------------------------------|-------|----------|------|---------|------------|
| Vascular function             | I/II  | 64       | 90 mg ResArg | ResArg had improved benefits for vascular function and platelet reactivity compared to RSV | Djurica et al., 2016 |
| Cardiovascular disease        | NA    | 27       | 300 or 1,000 mg RSV | Higher RSV dosage increased the cardiovascular disease biomarkers, lower RSV dose had no change | Mankowski et al., 2020 |
| Exercise-induced cardiovascular benefits | NA | 27 | 250 mg/day RSV 8 week | RSV diminished positive cardiovascular effects of exercise and had no effect on SIRT1 protein levels | Gliemann et al., 2013 |
| Congestive heart failure      | II    | 40       | 1,000 mg/day 8 week | Recruiting | NCT03525379 |
| Diabetic coronary artery disease | II    | 56       | 500 mg/day 4 week | RSV increased HDL, had beneficial effects on insulin resistance, and upregulated SIRT1 | Hoseini et al., 2019 |
| Peripheral artery disease     | III   | 90       | 125 mg RSV + 1,000 mg NR 6 m | Recruiting | NCT03743636 |
| Peripheral artery disease     | NA    | 66       | 125 or 500 mg/day | RSV had no consistent effect on walking performance in patients with peripheral artery disease | McDermott et al., 2017 |
| Hypertension                  | I/II  | 300      | 150 or 300 mg/day 12 m | Recruiting | NCT01842399 |
| Endothelial dysfunction       | I     | 24       | 300 mg | RSV treatment improved endothelial function, but had no effect on blood pressure | Marques et al., 2018 |
| Endothelial dysfunction       | NA    | 25       | 250 mg | RSV had small beneficial effect on endothelial function, but no additional benefit was seen with exercise | Ozemek et al., 2020 |

well. Although it is unclear if RSV can directly activate sirtuins when taken orally, it is likely that work with RSV will continue, as it is a readily available natural product with limited adverse reactions. Despite the early promise seen in the lab, the current reality of RSV has shown the need for developing better, more selective activators of sirtuins.

**Resveratrol-Related Activators**

Following the discovery of RSV, Sirtris began to develop new small molecule activators of SIRT1. From HTS, they discovered SIRT1 activators that were structurally distinct from RSV and had improved SIRT1 activating abilities (Milne et al., 2007). One of the compounds, SRT1720 (Figure 1), activated SIRT1 with an EC_{50} = 2.9 μM and a maximum activation of approximately 4.5-fold, whereas RSV had an EC_{50} = 46.2 μM and a maximum activation of 2-fold (Milne et al., 2007). Using ITC, it was determined that the SRT STACs could only bind SIRT1 in the presence of the peptide substrate and they had a mechanism of action similar to RSV. It was further found that they used the same binding site as RSV. In a rodent model of insulin resistance, SRT1720 treatment resulted in a decrease in the blood glucose level and an increase in insulin sensitivity (Milne et al., 2007).

Thus far, clinical trials of three compounds related to SRT1720 have been completed. SRT2104 (Figure 1) has the...
### TABLE 4 | Clinical trials of resveratrol for cognition and neurological disorders.

| Condition                        | Phase | Subjects | Dose | Outcome                                                                 | References                      |
|----------------------------------|-------|----------|------|-------------------------------------------------------------------------|---------------------------------|
| Alzheimer's disease              | III   | 27       | 10 g Dextrose, 10 g Malate, 10 mg RSV/day | RSV had small, but insignificant effects on mental deterioration | Zhu et al., 2018                |
| Alzheimer's disease              | II    | 119      | 500–2,000 mg/day | RSV and metabolites crossed the BBB; RSV decreased MMP9, neuroinflammation, and induced adaptive immunity | Turner et al., 2015; Moussa et al., 2017 |
| Brain function/structure         | NA    | 60       | 200 mg RSV, 320 mg Quercetin/day 18 week | No improvement in verbal memory after RSV treatment | Huhn et al., 2018               |
| Cognition and cerebral blood flow | NA    | 22       | 250, 500 mg | RSV increased cerebral blood flow, but no change in cognitive function was observed | Kennedy et al., 2010            |
| Cognition                        | NA    | 27       | 500 mg | No cognitive changes seen in healthy patients ages 18–35 | Wightman et al., 2019           |
| Cognitive impairment             | II/III| 40       | 200 mg/day 26 week | Beneficial, but non-significant changes in markers of diabetes and resting-state functional connectivity | Köbe et al., 2017               |
| Depression                       | III   | 22       | 500 mg/day 28 day | RSV did not have a significant antidepressant effect | Attanas et al., 2020            |
| Friedreich ataxia                | II/III| 27       | 1,000 or 5,000 mg/day 12 week | Improvement in oxidative stress markers and ataxia seen only in higher dosage group | Yiu et al., 2013                |
| Friedreich ataxia                | II    | 40       | 1,000 mg/day Micronized RSV | Recruiting | NCT03933163 |
| Gulf war illness                 | II    | 68       | 2,000 mg/day | Recruiting | NCT03665740 |
| Gulf war illness                 | NA    | 64       | 200–600 mg/day 4 week | RSV reduced Gulf War Illness symptoms | Hodgin et al., 2021             |
| Cognition                        | I     | 60       | 500 mg/day 28 day | RSV treatment reduced fatigue, but had no effect on sleep, health, or cerebral blood flow | Novelle et al., 2015            |
| Cognition                        | NA    | 24       | 500 mg | RSV treatment group had fewer errors in serial subtraction test | Wightman et al., 2019           |
| Schizophrenia                    | II    | 19       | 200 mg/day 4 week | RSV treatment did not improve cognition in patients with schizophrenia | Zortea et al., 2016             |
| Sports concussion                | I/II  | 12       | 500 mg/day 30 day | No significant effects seen with RSV treatment | NCT01321151 |

### TABLE 5 | Clinical trials of resveratrol for diabetes.

| Condition               | Phase | Subjects | Dose | Outcome                                                                 | References                  |
|-------------------------|-------|----------|------|-------------------------------------------------------------------------|-----------------------------|
| Dyslipidemia            | NA    | 50       | 150 mg/day 4 week | RSV treatment did not change cardiovascular or metabolic risk markers | van der Made et al., 2015  |
| Dyslipidemia            | I     | 8        | 1,000 mg/day, then 2,000 mg/day 2 week | RSV treatment reduced lipoprotein production | Dash et al., 2013           |
| Type 2 diabetes         | I     | 10       | 3,000 mg/day 12 week | RSV treatment increased SIRT1 and AMPK expression | Goh et al., 2014            |
| Type 2 diabetes         | NA    | 30       | 2,000–3,000 mg/day 6 week | No changes in T2D markers, but changes in expression of genes involved in mitochondrial activity | Pollack et al., 2017        |
| Type 2 diabetes         | NA    | 17       | 150 mg/day 30 day | RSV treatment did not improve insulin sensitivity | Timmers et al., 2018        |
| Insulin resistance      | NA    | 112      | 150 mg/day 12 week | RSV treatment did not impact liver fat content or cardiovascular risk factors | Kantartzis et al., 2018     |
| Type 2 diabetes         | NA    | 54       | 100 mg/day 2 week then 300 mg/day 2 week | RSV treatment decreased arterial stiffness and had a positive, but insignificant effect on SIRT1 activity | Zhang et al., 2017           |
| Type 2 diabetes         | III   | 192      | 40 or 500 mg/day 6 m | Higher RSV dosage group had increased SIRT1 levels and antioxidant markers, and decreased H3K56Ac and body fat percentage | Bo et al., 2018             |
| Pre-diabetes            | NA    | 15       | 150 mg/day 30 day | RSV increased muscle mitochondrial function, but no other metabolic benefits were observed | de Ligt et al., 2018        |
| Pre-diabetes            | I     | 48       | Recruiting | Recruiting | NCT02502253 |
| Pre-diabetes            | NA    | 42       | 150 mg/day 6 m | RSV had no effect on pre-diabetes markers | de Ligt et al., 2020        |
| Insulin resistance      | NA    | 270      | RSV + Vitamin C | Recruiting | NCT03090997 |
| Type 2 diabetes         | NA    | 40       | Recruiting | Recruiting | NCT03762066 |
| Type 1 diabetes         | NA    | 198      | Recruiting | Recruiting | NCT03436992 |
| Type 1 diabetes         | Early I | 24   | Recruiting | Recruiting | NCT04449198 |

greatest number of registered clinical trials (Table 10), but SRT2379 and SRT3025 (Figure 1) have also made it into the clinic (Table 11). The single clinical trial to assess the safety and pharmacokinetics of SRT3025 was interrupted after the researchers found a prolongation effect of SRT3025 on the corrected QT interval, a warning that continuation could lead to
### TABLE 6 | Clinical trials of resveratrol for inflammatory diseases.

| Condition                        | Phase | Subjects | Dose                  | Outcomes                                                                 | References                        |
|----------------------------------|-------|----------|-----------------------|--------------------------------------------------------------------------|-----------------------------------|
| Chronic kidney disease           | III   | 20       | 500 mg/day 4 week     | RSV treatment had no antioxidant or anti-inflammatory effects           | Saldanha et al., 2016             |
| Inflammatory markers             | NA    | 44       | 400 mg RSV + 100 mg Quercetin/day 30 day | RSV treatment had beneficial effect on some inflammatory markers and reduced fasting insulin concentration | Agarwal et al., 2013              |
| Inflammatory markers in smokers  | III   | 40       | 500 mg/day 30 day     | RSV treatment had beneficial effect on some inflammatory markers and the antioxidant level | Bo et al., 2013                   |
| Polycystic ovary syndrome        | NA    | 40       | 1,500 mg/day 3 m      | RSV treatment reduced ovarian and adrenal androgens                      | Banaszewska et al., 2016          |
| Inflammatory markers             | NA    | 22       | 200 mg RSV + 100 mg Curcumin | RSV/Curcumin treatment had no effect on inflammation after consumption of a high-fat meal | Vors et al., 2018                 |
| Endometriosis                    | III   | 44       | 40 mg/day 42 day      | RSV treatment had no effect on endometriosis pain                        | Mendes da Silva et al., 2017      |
| Osteoarthritis                   | III   | 164      | Recruiting            |                                                                           |                                   |
| Chronic kidney disease           | NA    | 25       | Recruiting            |                                                                           |                                   |

### TABLE 7 | Clinical trials of resveratrol for obesity and metabolic disorders.

| Condition                        | Phase | Subjects | Dose                  | Outcomes                                                                 | References                        |
|----------------------------------|-------|----------|-----------------------|--------------------------------------------------------------------------|-----------------------------------|
| Aging                            | II    | 60       | 500 or 1,000 mg/day 12 week | RSV treatment coupled with exercise had beneficial effects on physical and mitochondrial function | Harper et al., 2021               |
| Metabolism                       | I     | 32       | 300 or 1,000 mg/day 90 day | RSV treatment reduced glucose levels in overweight adults                | Anton et al., 2014                |
| Metabolic syndrome               | NA    | 25       | 250 mg/day 3 m         | RSV treatment improved many metabolic markers, including total cholesterol, urea, and creatinine | Batista-Jorge et al., 2020        |
| Metabolic syndrome               | II    | 24       | 1,500 mg/day 90 day    | RSV treatment reduced weight, BMI, and total insulin secretion           | Méndez-del Villar et al., 2014    |
| Obesity                          | NA    | 24       | 1,500 mg/day 4 week    | RSV treatment had no effect                                               | Poulsen et al., 2013              |
| Mitochondrial myopathy           | NA    | 20       | 1,000 mg/day 8 week    | RSV treatment did not improve exercise capacity in subjects with mitochondrial myopathy | Lekken et al., 2019               |
| Obesity                          | NA    | 18       | 150 mg/day 30 day      | RSV treatment had no effect on incretin levels, but reduced glucagon levels after eating in obese subjects | Knop et al., 2013                 |
| Metabolic syndrome               | NA    | 76       | 150 or 1,000 mg/day 16 week | RSV treatment did not improve inflammation and increased total cholesterol and LDL cholesterol in subjects with metabolic syndrome | Kjaer et al., 2017               |
| Metabolic syndrome               | NA    | 28       | 2,000 mg/day 30 day    | RSV treatment improvement insulin sensitivity for Caucasian subjects, but non-Caucasian subjects had no difference | Walker et al., 2018               |
| Metabolism                       | NA    | 58       | 75 mg/day 12 week      | RSV treatment had no effect on metabolic markers or SIRT1 expression     | Yoshino et al., 2012              |
| Obesity                          | NA    | 48       | 500 mg/day 30 day      | RSV treatment increased serum levels of SIRT1                            | Roggerio et al., 2018             |

### TABLE 8 | Clinical trials of resveratrol for NAFLD.

| Condition | Phase | Subjects | Dose                  | Outcome                                           | References                        |
|-----------|-------|----------|-----------------------|---------------------------------------------------|-----------------------------------|
| NAFLD     | II/III| 50       | 500 mg/day 12 week    | RSV treatment improved inflammatory markers        | Faghihzadeh et al., 2014          |
| NAFLD     | NA    | 28       | 1,500 mg/day 6 m      | RSV had no consistent beneficial effect for NAFLD | Heebell et al., 2016              |
| NAFLD     | NA    | 90       | 600 mg/day 12 week    | RSV treatment led to weight loss, but did not change SIRT1 level or induce other beneficial effects of CR | Asghari et al., 2018              |
| NAFLD     | NA    | 26       | 1,500 mg/day 6 m      | RSV treatment had no effect on metabolic markers for subjects with NAFLD | Poulsen et al., 2018              |

a potentially fatal proarrhythmia in the subjects (NCT01340911, GSK Study Register). Further development of SRT2379 was also terminated due to preclinical toxicities observed by the researchers (NCT01416376, GSK Study Register).

For the lead compound, SRT2104, 5 out of the 8 clinical trials that focused on clinical outcomes had neutral or statistically insignificant results. A pharmacokinetic study found that the bioavailability of SRT2104 was 14% and exposure was improved when administered with food (Hoffmann et al., 2013). Most trials observed highly variable pharmacokinetics, leading some to have inconsistent clinical outcomes. A few trials observed beneficial effects of SRT2104 treatment on lipid profiles (Baksi et al., 2014),
### TABLE 9 | Clinical trials of resveratrol for respiratory conditions.

| Condition       | Phase | Subjects | Dose                          | Outcome                                                                 | References |
|-----------------|-------|----------|-------------------------------|-------------------------------------------------------------------------|------------|
| Common cold     | III   | 89       | Nasal solution of RSV/carboxymethyl-β-glucan | c β G/RSV treatment provided minor benefit for nasal symptoms in infants | Baldassarre et al., 2020 |
| COPD            | NA    | 21       | 150 mg/day 4 week             | RSV treatment did not improve mitochondrial function in subjects with COPD | Beijers et al., 2020 |
| Seasonal allergies | III  | 76       | Nasal solution of RSV/carboxymethyl-β-glucan | c β G/RSV treatment reduced nasal symptoms | Miraglia Del Giudice et al., 2014 |
| COPD            | NA    | 48       | Recruiting                   |                                                                          | NCT03819517 |
| Cystic fibrosis | NA    | 36       | Active, not recruiting        |                                                                          | NCT04166396 |
| COVID-19        | II    | 100      | Recruiting                   |                                                                          | NCT0440090 |
| COVID-19        | II    | 60       | Active, not recruiting        |                                                                          | NCT04542993 |
| COVID-19        | NA    | 30       | Recruiting                   |                                                                          | NCT04799743 |

### TABLE 10 | Clinical trials on SRT2104.

| Condition       | Phase | Subjects | Dose                          | Outcome                                                                 | References |
|-----------------|-------|----------|-------------------------------|-------------------------------------------------------------------------|------------|
| Pharmacokinetics | I     | 20       | 500 mg                        | SRT2104 had increased absorption with ingested with food; Headache was most common AE | Hoffmann et al., 2013 |
| Type 2 Diabetes | I     | 10       | 2,000 mg/day 7 day            | SRT2104 increased after multiple doses; Headache was the most common AE (affecting 50% of the treatment group) | Hoffmann et al., 2013 |
| COPD            | I     | 20       | 250–2,000 mg                  | SRT2104 had no effect on inflammatory markers; variable pharmacokinetic parameters | NCT00920660, GSK Study Register |
| Muscular atrophy | I     | 24       | 500 or 2,000 mg/day 28 day    | SRT2104 treatment decreased cholesterol and LDL levels, but had variable pharmacokinetics. | Libri et al., 2012 |
| Sepsis/Inflammation | I     | 24       | 2,000 mg/day 7 day            | SRT2104 treatment had anti-inflammatory and anticoagulant effects | van der Meer et al., 2015 |
| Type 2 diabetes | I     | 38       | 2,000 mg/day 28 day           | SRT2104 treatment had a beneficial metabolic effect and improved lipid profiles and arterial stiffness. It had inconsistent effects on endothelial function | Venkatasubramanian et al., 2013, 2016; Noh et al., 2017 |
| Psoriasis       | II    | 40       | 250, 500, 1,000 mg/day 84 day | 35% of SRT2104 treatment group had improvement in psoriasis; 69% had AEs; SRT2104 exposure was highly variable | Krueger et al., 2015 |
| Type 2 diabetes | II    | 86       | 2,000 mg/day 28 day           | SRT2104 had no consistent effects on insulin sensitivity               | NCT01018017, GSK Study Register |
| Type 2 diabetes | I     | 227      | 250–2,000 mg/day 28 day       | SRT2104 did not improve glucose or insulin control; Exposure was highly variable | Baksi et al., 2014 |
| Ulcerative colitis | II   | 17       | 50,500 mg/day 8 week          | SRT2104 did not improve UC                                              | Sands et al., 2016 |
| Pharmacokinetics | I     | 65       | 30–3,000 mg/day 7 day         | SRT2104 bioavailability was 14%; Administration with food increased drug exposure | Hoffmann et al., 2013 |

### TABLE 11 | Clinical trials of SRT2379 and SRT3025.

| Condition       | Phase | Subjects | Dose                          | Outcome                                                                 | References |
|-----------------|-------|----------|-------------------------------|-------------------------------------------------------------------------|------------|
| Type 2 diabetes | I     | 64       | 25–3,000 mg SRT2379           | SRT2379 exposure increased in a dose-dependent manner                   | NCT01018628, GSK Study Register |
| Inflammation    | I     | 17       | 1,000 mg SRT2379             | SRT2379 treatment had a trend of anti-inflammatory effects, but was not statistically significant | NCT01262911, GSK Study Register |
| Inflammation    | I     | 39       | 50–1,000 mg SRT2379          | SRT2379 treatment did have a significant anti-inflammatory effect       | Wiewel et al., 2013 |
| Type 2 diabetes | I     | 78       | 50–3,000 mg SRT3025          | SRT3025 treatment stopped due to potential adverse cardiovascular side effects | NCT01340911, GSK Study Register |

Histological examinations of subjects with psoriasis (Krueger et al., 2015), and inflammation (van der Meer et al., 2015). McCallum et al. (2014) tried to improve the pharmacokinetics of SRT2104 by using different release formulations, but were unsuccessful. As of current, it appears that SRT2104 is no longer in development. Despite issues observed in clinical trials, SRT2104 continues to be used in studies as a SIRT1 activator (Miller et al., 2021).
The isoform selectivity of EX-527 was initially necessary for an effective inhibition and modifications to the lead compound were generally not well tolerated (Napper et al., 2005). The isoform selectivity of EX-527 was initially attributed to possible differences among the sirtuin active sites (Bedalov et al., 2001; Grozinger et al., 2001; Bitterman et al., 2002; Mai et al., 2005; Olaharski et al., 2005; Porcu and Chiarugi, 2005). Isoform-selective small molecule probes were highly sought after for a better understanding of the biological functions of these enzymes (Porcu and Chiarugi, 2005). Napper et al. (2005) performed an HTS of a library of 280,000 compounds against human recombinant SIRT1 using a fluorometric assay in order to expand available SIRT1 small-molecule probes. The initial screening identified indole as a viable scaffold for SIRT1 targeting. The subsequent SAR study led to the discovery of EX-527 (or Selisistat) and the structurally related compound CHIC-35 (Figure 3) as selective SIRT1 inhibitors with IC\textsubscript{50} values of 0.098 and 0.063 µM, respectively (Napper et al., 2005). EX-527 exhibited 100-fold selectivity for SIRT1 over SIRT2/3, Class I/II HDACs, and NAD\textsuperscript{+} glycohydrolase (Napper et al., 2005). Kinetic studies indicated that EX-527 is an uncompetitive inhibitor of SIRT1 regarding NAD\textsuperscript{+}; thus, inhibition depends on the concentration of NAD\textsuperscript{+} (Napper et al., 2005; Gertz et al., 2013). Additionally, EX-527 exhibits exceptional ADME properties such as oral bioavailability, metabolic stability, and membrane penetrability, thus elevating EX-527 from a small-molecule probe to a therapeutic candidate (Napper et al., 2005).

In contrast, the study of CHIC-35 has been limited to pre-clinical investigations, primarily on its anti-inflammatory effects (Lugrin et al., 2013). SAR studies of EX-527 revealed that the primary carboxamide was necessary for an effective inhibition and modifications to the lead compound were generally not well tolerated (Napper et al., 2005). The isoform selectivity of EX-527 was initially attributed to possible differences among the sirtuin active sites (Gertz et al., 2013; Broussy et al., 2020). A recent structural biology study suggested that EX-527 occupies the C-pocket (nicotinamide binding site) and a neighboring hydrophobic pocket which are highly conserved in the sirtuin family (Gertz et al., 2013). Further kinetic analysis indicated that the isoform selectivity of EX-527 stemmed from the differences in the kinetics of catalysis rather than any significant structural variation (Gertz et al., 2013; Broussy et al., 2020).

EX-527 has been explored as a potential therapeutic for Huntington's disease (HD). HD is a neurodegenerative disease characterized by abnormal movements, personality changes, and cognitive decline (Bates et al., 2015). A hallmark of HD is the expression of the mutant Huntington gene (mHTT), which has an expansion of a cytosine-adenine-guanine (CAG) repeat (Bates et al., 2015; Tabrizi et al., 2020). This extension leads to the protein misfolding and the formation of protein aggregates in HD patients (Bates et al., 2015; Tabrizi et al., 2020). As such, a potential therapeutic approach has focused on the degradation and removal of these aggregates. Acetylation of mHTT can direct the protein to autophagosomes for degradation (Jeong et al., 2009), thus facilitating the removal of the mutant protein. SIRT1 has been pursued as a therapeutic target for the treatment of HD because it has been shown to deacetylate mHTT to prevent its degradation. Genetic loss or pharmacological inhibition of Sir2 (the Drosophila melanogaster homolog of human SIRT1) was found to be neuroprotective for mHTT-challenged fruit flies (Pallos et al., 2008). Indeed, Smith et al. (2014) demonstrated that in a Drosophila model of HD, 10 µM of EX-527 could rescue neurodegeneration at a comparable level as the genetic elimination of Sir2. Additionally, in the R6/2 mouse model of HD, EX-527 can restore neural functions at 5 and 20 mg/kg dosages (Smith et al., 2014). It is important to note that the role of SIRT1 in HD remains controversial, as some view it as protective in HD modulation (Duan, 2013).

The aforementioned preclinical animal studies were essential for clinical trials involving EX-527 as an HD treatment option (Table 12). In a Phase 1 trial (NCT01521832), EX-527 was assessed for its safety in healthy human subjects. The study employed healthy men and women with two separate dosage regimens: a single dosage of 5, 25, 75, 150, 300, or 600 mg, and multiple dosages of 100, 200, or 300 mg/day (Westerberg et al., 2015). In this study, EX-527 was found to be well-tolerated and safe after multiple doses of 300 mg/day and at a single dose of 600 mg. Based on the promising safety profile and dosing information, another clinical trial (NCT01485952)
sought to investigate the feasibility of targeting SIRT1 as a potential treatment for HD (Sussmuth et al., 2015). In this study, human subjects with HD were treated with either 0, 10, or 100 mg/day of EX-527. There were improvements across the clinical, cognitive, and neuropsychiatric assessments from the baseline (day -1) to day 1 with no additional improvement at day 14 (Sussmuth et al., 2015).

A relatively new clinical application of EX-527 is improving in vitro fertilization (IVF) outcomes through the treatment of endometriosis (NCT04184323). Endometriosis is a chronic inflammatory reproductive disorder involving the growth of uterine endometrial cells outside of the uterine cavity (Zondervan et al., 2020). These delocalized endometrial growths can become lesions that lead to chronic localized pelvic pain and cramping with accompanying fertility issues. Standard treatment options for endometriosis involve mechanical lesion removal, hormonal therapy, or a combination of the two (Budinetz and Sanfilippo, 2010). However, reemergence of the lesions and complications associated with the hormonal therapy remain limitations. Thus, alternative treatment options are needed. A recent study demonstrated a KRAS activation-triggered SIRT1 overexpression in women with endometriosis, which has been suggested to contribute to infertility and the pathogenesis of endometriosis (Yoo et al., 2017). Targeting SIRT1 with small molecule inhibitors thus serves as a potential therapeutic treatment for endometriosis-mediated IVF failure. A planned clinical trial (NCT04184323) will seek to explore inhibition of SIRT1 by EX-527 as a possible treatment for the inflammation associated with endometriosis.

QUERCETIN

Quercetin (Figure 4) is a flavonoid phytoestrogen which has demonstrated activity in the management of brain, blood, salivary gland and uterine cancers (Dolatabadi, 2011; Sak, 2014; Sinaga et al., 2017), as well as viral infections such as HCV (Rojas et al., 2016) and Zika virus (Wong et al., 2017) and bacterial infections (Wang et al., 2018; Zeng et al., 2019; Oktjabrsky et al., 2020) in both in vivo and in vitro studies. The structure of quercetin consists of three rings and five hydroxyl groups at the 3, 5, 7, 3′ and 4′-positions of the basic flavanol skeleton (Figure 4). The name “quercetin” was derived from the Latin word “Quercetum” which means oak forest. It is one of the most abundant flavonoids found in fruits and vegetables, and was discovered alongside other bioflavonoids by Albert Szent Gyorgyi in 1936 (Moskaug, Carlsen et al., 2004).

In the same HTS that identified RSV, quercetin was observed to increase SIRT1 activity by fivefold (Howitz et al., 2003). Studies have shown the inhibitory role of quercetin on the progression of breast, colon, prostate, and lung cancers (Baghel et al., 2012; Smith et al., 2016). Quercetin has been found to alleviate kidney fibrosis, intervertebral disc degeneration, and diabetic encephalopathy via activation of SIRT1-mediated pathways (Dong et al., 2014; Hu et al., 2020; Liu et al., 2020). Quercetin treatment of Herpes simplex virus-1 infected neuronal cell lines increased the survival of the cells by inhibiting viral production and improved neurodegenerative markers via SIRT1 activation (Leyton et al., 2015). It was also found that quercetin inhibits oxidative injury in human endothelial cells through SIRT1 activation, leading to the upregulation of the SIRT1/AMPK pathway (Chen et al., 2013). In addition, quercetin regulates oxidative stress in the body by directly reducing the level of reactive oxygen species (Oboh et al., 2016). In myocardial/ischemia-reperfusion (MI/R) injury in rats, quercetin supplementation increased the expression levels of SIRT1 and PGC-1α, leading to the activation of the SIRT1/PGC-1α pathway and subsequent reduction in MI/R-induced myocardial damage (Tang et al., 2019). In addition to SIRT1, quercetin has a mild stimulating effect on SIRT6 (You et al., 2019). When modified with a bulky trihydroxy benzoyl group at the 3-OH group, as in catechin gallate, it inhibits SIRT6 activity (Rahnasto-Rilla et al., 2018; You et al., 2019).

Quercetin exists as a glycone or an aglycone in plants. When ingested, the glycone form can be hydrolyzed to the aglycone form that can be easily absorbed in the small intestine due to its hydrophobic nature (Massi et al., 2017). In human plasma, ingested quercetin glycosides are predominantly metabolized into quercetin 3-O-β-D-glucuronide and quercetin 3′-O-sulfate (Figure 4; D’Andrea, 2015; Moodi et al., 2021). Modifications such as glycosylation and methylation of the quercetin scaffold result in derivatives with distinct biological activities (Lesjak et al., 2018). For example, isoquercetin, the 3-O-glucoside of quercetin (Magar and Sohng, 2020), demonstrates

![Figure 4](https://example.com/figure4.png) Chemical structures of quercetin and its derivatives.
SIRT6 stimulation activity with no influence on SIRT1 activity (You et al., 2019).

Quercetin's therapeutic applications have been limited by its low bioavailability, poor solubility, and short half-life (Gugler et al., 1975; Ferry et al., 1996; Kaşkı and Bağdatlıoğlu, 2016). Modifications have been made to improve these properties (Massi et al., 2017). In one study, the bioavailability of quercetin was increased by about 20 times through a phytosome delivery system (Riva et al., 2019). Several other studies have utilized conjugation to various amino acids and nanoparticle delivery systems to improve the bioavailability of quercetin. Acylated quercetin analogs synthesized by Duan et al. (2017) were about 10-fold more soluble in water than quercetin. Of the several quercetin human clinical trials targeting various disease states, only one ongoing study (NCT03943459) is aimed at investigating the activation of SIRT1 by quercetin in coronary disease.

CONCLUSION AND PERSPECTIVES

A simple search in PubMed provides hundreds of publications related to sirtuin inhibitor/activator development, demonstrating the critical roles these enzymes play in regulating diverse cellular events and the intense interest in pursuing them as therapeutic targets. Unfortunately, tremendous efforts have only resulted in a handful of small molecules in clinical studies as described in this review article. Translating sirtuin regulators from the bench to the clinics has been hampered by the lack of isoform-selective candidate compounds with favorable pharmacological profiles. The catalytic domain is highly conserved between sirtuins and therefore represents a promiscuous target for NAD$^+$ or peptide-competitive inhibitors (Dai et al., 2018). In the case of activators, the binding sites are often not readily apparent by the inspection of a crystal structure, and there is no general and systematic strategy to identify and target these sites. Furthermore, for several human sirtuin isoforms, novel enzymatic activities were discovered recently (Du et al., 2011; Feldman et al., 2013; Jiang et al., 2013; Anderson et al., 2017). Potent regulators targeting specifically these new activities are still in the making. Pre-clinical investigations using animal models may differ in the genetic background or the assessment methods which have caused controversies and ambiguities that still need to be reconciled. In spite of numerous reports on the endogenous substrates of sirtuins and the pathways they regulate, our understanding of the biological functions of sirtuins is still in its infancy. For example, SIRT1 has been closely associated with cancer pathology, and has been suggested as either a tumor promoter or a suppressor in a context-dependent manner (Deng, 2009). All the research effort has only scratched the surface of sirtuin biology. A comprehensive and thorough picture of these intriguing enzymes still awaits description.

Of course, sirtuin-targeting drugs still hold great therapeutic potential, and progress in the field will accelerate the development of small molecule drug candidates. Apart from their highly conserved catalytic core, sirtuins harbor structurally unique N- or C-terminal extensions that can be targeted for selectivity or even specificity. The conformational plasticity of the active site that explains the isoform selectivity of EX-527 (Gertz et al., 2013; Broussy et al., 2020) has also been suggested as a novel target for inhibitor development. The clinical success of sirtuin-targeting medications requires a clear understanding of the “sirtuin-dependency” of the disease, robust lead compounds that are potent and selective with ideal drug-like properties, PK/PD profiling and improvement, as well as advances in formulation. The combined efforts from all these aspects will bring more sirtuin regulators into the clinic for treating diseases with considerable unmet medical needs.

AUTHOR CONTRIBUTIONS

AC, DW, and YC: conceptualization. AC, DW, DD, and YC: writing. YC: project administration and funding acquisition. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported in part by CHE-1846785 from NSF (to YC), 2020 VCU CCTR Endowment Fund (subaward of UL1TR002649 from National Center for Advancing Translational Sciences to VCU) (to YC), Jeffress Trust Award in Interdisciplinary Research from Thomas F. and Kate Miller Jeffress Memorial Trust and Bank of America (to YC), 2020 Presidential Research Quest Fund from VCU (to YC), and start-up funds from VCU (to YC).

REFERENCES

Afanas, L. I., Markov, A. A., Rikita, M. V., and Danilenko, K. V. (2020). P.326 Efficacy of resveratrol in the treatment of unipolar depression: double-blind randomized placebo-controlled parallel-group study. Eur. Neuropsychopharmacol. 40:5189.

Agarwal, B., Campen, M. J., Channell, M. M., Wherry, S. J., Varamini, B., Davis, J. G., et al. (2013). Resveratrol for primary prevention of atherosclerotic: clinical trial evidence for improved gene expression in vascular endothelium. Int. J. Cardiol. 166, 246–248. doi: 10.1016/j.ijcard.2012.09.027

Anderson, K. A., Huryn, F. K., Fisher-Wellman, K., Stuart, J. D., Peterson, B. S., Douros, J. D., et al. (2017). SIRT4 is a lysine deacetylase that controls leucine metabolism and insulin secretion. Cell Metab. 25, 838–855.e15. doi: 10.1016/j.cmet.2017.03.003

Anton, S. D., Embry, C., Marsiske, M., Lu, X., Doss, H., Leeuwenburgh, C., et al. (2014). Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp. Gerontol. 57, 181–187. doi: 10.1016/j.exger.2014.05.015

Arias, N., Macarulla, M. T., Aguirre, L., Milton, I., and Portillo, M. P. (2016). The combination of resveratrol and quercetin enhances the individual effects of these molecules on triacylglycerol metabolism in white adipose tissue. Eur. J. Nutr. 55, 341–348. doi: 10.1007/s00394-015-0854-9

Asad, Z., and Sachidanandan, C. (2020). Chemical screens in a zebrafish model of CHARGE syndrome identifies small molecules that ameliorate disease-like...
Du, J., Zhou, Y., Su, X., Yu, J. J., Khan, S., Jiang, H., et al. (2011). Sirt5 is a NAD-dependent protein lysine deacylase and desuccinylase. Science 334, 804–807.

Duan, W. (2013). Targeting sirtuin-1 in Huntington’s disease: rationale and current status. CNS Drugs 27, 345–352. doi: 10.1007/s40263-013-0055-0

Duan, Y., Sun, N., Xue, M., Wang, X., and Yang, H. (2017). Synthesis of regioselectively acylated quercetin analogues with improved antiplatelet activity. Mol. Med. Rep. 16, 9735–9740. doi: 10.3892/mmr.2017.7781

Endres, K., and Fahrenholz, F. (2012). The role of the anti-amyloidogenic secretase ADAM10 in shedding the app-like proteins. Curr. Alzheimer Res. 9, 157–164. doi: 10.2174/15672051279931664

Faghizadeh, F., Adibi, P., Rafiei, R., and Hekmatdoost, A. (2014). Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr. Res. 34, 837–843. doi:10.1016/j.nutres.2014.09.005

Feldman, J. L., Baeza, J., and Denu, J. M. (2013). Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins. J. Biol. Chem. 288, 31330–31336. doi:10.1074/jbc.C113.112617

Ferry, D. R., Smith, A., Malkhandi, J., Fyle, D. W., deTakats, P. G., Anderson, D., et al. (1996). Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. 2, 659–668.

Gertz, M., Fischer, F., Nguyen, G. T., Lakshminarasimhan, M., Schütkowski, M., Weyand, M., et al. (2013). Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc. Natl. Acad. Sci. U.S.A. 110, E2772–E2781. doi:10.1073/pnas.1403628110

Gliemann, L., Schmidt, J. F., Olesen, J., Biensø, R. S., Peronard, S. L., Grandjean, N., and evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339, 1216–1219. doi:10.1126/science.1231097

Hodgin, K. S., Donovan, E. K., Kekes-Szabo, S., Lin, J. C., Feick, J., Massey, C., Herskovits, A. Z., and Guarente, L. (2014). SIRT1 in neurodevelopment and brain senescence. Neuron 81, 471–483. doi:10.1016/j.neuron.2014.01.028

Hofmann, E., Wald, J., Laval, S., Roberts, J., Beaumont, C., Haddad, J., et al. (2013). Pharmacokinetics and tolerability of SIRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br. J. Clin. Pharmacol. 75, 186–196. doi:10.1111/bcp.12152.2012.04340.x

Hoseini, A., Namazi, G., Farrokhiyan, A., Reiner, Z., Aghadavod, E., Bahmani, F., et al. (2019). The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Food Funct. 10, 6042–6051. doi: 10.1039/c9fo01075k

Hou, X., Rooklin, D., Fang, H., and Zhang, Y. (2016). Resveratrol serves as a protein-substrate interaction stabilizer in human SIRT1 activation. Sci. Rep. 6:38186. doi: 10.1038/srep38186

Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., et al. (2011). Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases—safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 4, 1419–1425. doi: 10.1158/1940-6207.CAPR-11-0148

Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Laval, S., Wood, J. G., et al. (2003). Small molecule activators of sirtuins extend Sca1theromies cleviasis lifespan. Nature 425, 191–196. doi: 10.1038/nature01960

Hubbard, B. P., Gomes, A. P., Dai, H., Li, J., Case, A. W., Considine, T., et al. (2013). Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339, 1216–1219. doi:10.1126/science.1231097

Huhn, S., Beyer, F., Zhang, R., Lampe, L., Grothe, J., Kratzsch, J., et al. (2018). Effects of resveratrol on memory performance, hippocampus connectivity and microstructure in older adults – A randomized controlled trial. Neuroimage 174, 177–190.

Jiang, J. J., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., et al. (2013). SIRT5 is a CURry et al. Human Sirtuin Regulators
incrinetic hormone responses, but suppresses postprandial glucagon in obese subjects. *Diabet. Med. 30*, 1214–1218.

Köbe, T., Witte, A. V., Schnelle, A., Tesky, V. A., Pantel, J., Schuchardt, J.-P., et al. (2017). Impact of resveratrol on glucose control, hippocampal structure and connectivity, and memory performance in patients with mild cognitive impairment. *Front. Neurosci.* 11:105. doi: 10.3389/fnns.2017.00105

Kosciuk, T., Wang, M., Hong, J. Y., and Lin, H. (2019). Updates on the epigenetic roles of sirtuins. *Curr. Opin. Chem. Biol.* 51, 18–29.

Krueger, J. G., Suárez-Farfánas, M., Cueto, I., Khacharian, A., Matheson, R., Parish, L. C., et al. (2015). A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis. *PLoS One* 10:e0142081. doi: 10.1371/journal.pone.0142081

Kumar, S., and Lombard, D. B. (2018). Functions of the sirtuin deaclyase SIRT5 in normal physiology and pathobiology. *Crit. Rev. Biochem. Mol. Biol.* 53, 311–334. doi: 10.1080/10409238.2018.1458071

Lakshminarasimhan, M., Rauh, D., Shutkowski, M., and Steegborn, C. (2013). SIRT1 activation by resveratrol is substrate sequence-selective. *Aging 5*, 151–154. doi: 10.18632/aging.100542

Landry, J., Sutton, A., Tafrov, S. T., Heller, R. C., Stebbins, J., Pillus, L., et al. (2000). The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. *Proc. Natl. Acad. Sci. U.S.A.* 97, 5807–5811.

Lesjak, M., Beara, I., Sinin, N., Pintač, D., Majčík, T., Bekvalac, K., et al. (2018). Antioxidant and anti-inflammatory activities of quercetin and its derivatives. *J. Funct. Foods* 40, 68–75.

Leyton, L., Hott, M., Acuña, F., Caroca, J., Nuñez, M., Martin, C., et al. (2015). Nutraceutical activators of AMPK/Sirt1 axis inhibit viral production and protect neurons from neurodegenerative events triggered during HSV-1 infection. *Virus Res.* 205, 63–72. doi: 10.1016/j.virusres.2015.05.015

Libri, V., Brown, A. P., Gambarota, G., Haddad, J., Shields, G. S., Dawes, H., et al. (2013). Sirtuin activation targets IDH-mutant tumors. *Nature 490*, 712–716. doi: 10.1038/nature11350

Lokken, N., Khawajazada, T., Storgaard, J., Raaschou-Pedersen, D., Ørngreen, M., and Vissing, J. (2019). SIRT1-dependent regulation of deacetylase SIRT1. *Biochim. Biophys. Acta* 1862, 1640–1649. doi: 10.1016/j.bbamcr.2018.11.004

Lukin, C., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001). Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. *Nature 450*, 712–716.

Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., et al. (2010). Acetylation of tau inhibits its degradation and contributes to tautopathy. *Neuron 67*, 953–966.

Napper, A. D., Hixon, J., McDonagh, T., Keavey, K., Pons, J. F., Barker, J., et al. (2005). Quercetin as a precursor for the novel SIRT1 activator SRT2104 (GSK2245840B), *in Proceedings of the 2014 Annual Meeting & Exposition - American Association of Pharmaceutical Scientists, San Diego, CA.*

McDermott, M. M., Leeuweneburg, C., Guralnik, J. M., Tian, L., Sufit, R., Zhao, J. (2017). Effect of resveratrol on walking performance in older people with peripheral artery disease: the RESTORE randomized clinical trial. *JAMA Cardiol.* 2, 902–907. doi: 10.1001/jamacardio.2017.0538

McDermott, M. M., Leeuweneburg, C., Guralnik, J. M., Tian, L., Sufit, R., Zhao, J. (2017). The use of resveratrol as an adjuvant treatment of pain in endometriosis: a randomized clinical trial. *J. Endocr. Soc. 1*, 359–369. doi: 10.1210/js.2017-00053

Mendez-del Villar, M., Gonzalez-Ortiz, M., Martinez-Abundis, E., Pérez-Rubio, K. G., and Lizarraga-Valdez, R. (2014). Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. *Metab. Syndr. Relat. Disord.* 12, 497–501.

Miller, J. J., Fink, A., Banagis, J. A., Nagashima, H., Subramanian, M., Lee, C. K., et al. (2021). Sirtuin activation targets IDH-mutant tumors. *Nature Neuron 23*, 53–62. doi: 10.1038/s41590-018-0040-0

Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., et al. (2007). Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. *Nature 450*, 712–716.

Moodi, Z., Bagherzade, G., and Peters, J. (2021). Quercetin as a precursor for the novel SIRT1 activator SRT2104 (GSK2245840B), *in Proceedings of the 2014 Annual Meeting & Exposition - American Association of Pharmaceutical Scientists, San Diego, CA.*

Moskaug, J. Ø., Carlsen, H., Myhrstad, M., and Blomhoff, R. (2004). Molecular mechanisms of Sirtuin 1 (SIRT1) and the sirtuin deacetylase SIRT2. *Antioxid. Redox Signal* 6, 11:105. doi: 10.1186/1465-9964-6-105

Napper, A. D., Hixon, J., McDonagh, T., Keavey, K., Pons, J. F., Barker, J., et al. (2005). Discovery of Indoles as Potent and Selective Inhibitors of the Deacetylase SIRT1. *J. Med. Chem.* 48, 8045–8054.
Noh, R. M., Venkatasubramanian, S., Daga, S., Langrish, J., Mills, N. L., Lang, N. N., et al. (2017). Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus. *Open Heart* 4:e000647. doi: 10.1136/openhrt-2017-000647

Novelle, M., Wahl, D., Diéguez, C., Bernier, M., and de Cabo, R. (2015). Resveratrol supplementation: Where are we now and where should we go? *Aging Res. Rev.* 21, 1–15. doi: 10.1016/j.arr.2015.01.002

Ohbo, G., Ademosun, A. O., and Ogunsuyi, O. B. (2016). Quercetin and its role in chronic diseases. *Adv. Exp. Med. Biol.* 929, 377–387.

Oktaybyski, O. N., Bezmaternykh, K. V., Smirnova, G. V., and Tyulenev, A. V. (2020). Biotechnoeffect. Effect of resveratrol and quercetin on the susceptibility of *Escherichia coli* to antibiotics. *World J. Microbiol. Biotechnol.* 36:167. doi: 10.1007/s11274-020-02934-y

Olaharski, A. J., Rine, J., Marshall, B. L., Babiarz, J., Zhang, L., Verdin, E., et al. (2016). Quercetin and its role in viral to host targets. *Sci. Rep.* 6:31777. doi: 10.1038/srep31777

Sak, K. (2014). Site-specific anticancer effects of dietary flavonoid quercetin. *Nutr. Cancer* 66, 177–193.

Saldanha, J. F., Leal, V. O., Rizzetto, F., Grimmer, G. H., Ribeiro-Alves, M., Daleprane, J. B., et al. (2016). Effects of Resveratrol Supplementation in Nr2f and NF-xB Expressions in nondiabetic chronic kidney disease patients: a randomized, double-blind, placebo-controlled, crossover clinical trial. *J. Ren. Nutr.* 26, 401–406. doi: 10.1053/j.jrn.2016.06.005

Sandb, B. E., Joshi, S., Haddad, J., Freudenberg, J. M., Oommen, D. D., Hoffmann, E., et al. (2016). Assessing colonic exposure, safety, and clinical activity of SRT2104, a Novel Oral SIRT1 activator, in patients with mild to moderate ulcerative colitis. *Inflamm. Bowel Dis.* 22, 607–614. doi: 10.1093/IBD/iiz109

Sauve, A. W., Wolberger, C., Schramm, V. L., and Boeke, J. D. (2006). The biochemical chemistry of sirtuins. *Annu. Rev. Biochem.* 75, 435–465.

Schmidt, C. (2010). GSK/Sirtis compounds dogged by assay artifacts. *Nat. Biotechnol.* 28, 185–186. doi: 10.1038/nbt0310-185

Shahbazian, M. D., and Grunstein, M. (2007). Functions of site-specific histone acetylation and deacetylation. *Annu. Rev. Biochem.* 76, 75–100.

Sinaga, S., Sudarmi, S., Iksen, I., Kevin, K., and Sari, M. J. (2017). Evaluation of total anthocyanin, phenolic, flavonoid content, antioxidant and in vitro antiproliferative activities in liver and small intestine of rat and guinea pig in vitro by piperez. *Rasayan J. Chem.* 10:1925.

Tan, J., Yu, L., Liu, T., Yang, M., Li, L., et al. (2019). Quercetin improve ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro and in vivo study via SIRT1/PGC-1α signaling. *J. Cell. Biochem.* 120, 9747–9757.

Timmers, S. D., Haider, S., Landewehmeyer, G. B., Farmer, R., Frost, C., Tripepi, G., et al. (2015). An exploratory double-blind, randomized clinical trial with selisitam, a Sirt1 inhibitor, in patients with Huntington's disease. *Br. J. Clin. Pharmacol.* 79, 465–476.

Tobrizi, S. J., Flower, M. D., Ross, C. A., and Wild, E. J. (2020). Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. *Nat. Rev. Neurol.* 16, 529–546.

Wang, J., Lu, L., Liu, C., Wang, Y., Li, L., et al. (2019). Quercetin improve ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro and in vivo study via SIRT1/PGC-1α signaling. *J. Cell. Biochem.* 120, 9747–9757.

Timmers, S. D., Haider, S., Landewehmeyer, G. B., Farmer, R., Frost, C., Tripepi, G., et al. (2015). An exploratory double-blind, randomized clinical trial with selisitam, a Sirt1 inhibitor, in patients with Huntington's disease. *Br. J. Clin. Pharmacol.* 79, 465–476.

Tobrizi, S. J., Flower, M. D., Ross, C. A., and Wild, E. J. (2020). Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. *Nat. Rev. Neurol.* 16, 529–546.
resveratrol for Alzheimer disease. *Neurology* 85, 1383–1391. doi: 10.1212/WNL.0000000000002035

Ung, D., and Nagar, S. (2007). Variable sulfation of dietary polyphenols by recombinant human sulfotransferase (SULT) 1A1 genetic variants and SULT1E1. *Drug Metab. Dispos.* 35, 740–746. doi: 10.1124/dmd.016109

Wang, S., Yao, J., Zhou, B., Yang, J., Chaudry, M. T., Wang, M., et al. (2018). The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: a pilot randomized, placebo-controlled clinical trial. *J. Clin. Transl. Res.* 4, 122–135.

Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E. Jr., and Walle, U. K. (2004). High absorption but very low bioavailability of oral resveratrol in humans. *Drug Metab. Dispos.* 32, 1377–1382. doi: 10.1124/dmd.104.000885

Wang, S., Yao, J., Zhou, B., Yang, J., Chaudry, M. T., Wang, M., et al. (2018). Bacteriostatic effect of quercetin as an antibiotic alternative in vivo and its antibacterial mechanism in vitro. *J. Food Prot.* 81, 68–78. doi: 10.4315/0362-028X.JFP-17-214

Wang, Z., Yuan, H., Roth, M., Stark, J. M., Bhatia, R., and Chen, W. Y. (2013). SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. * Oncogene* 32, 588–598. doi: 10.1038/onc.2012.83

Watroba, M., Dudek, I., Skoda, M., Stangret, A., Rzodkiewicz, P., and Szuikiewicz, D. (2017). Sirtuins, epigenetics and longevity. *Ageing Res. Rev.* 40, 11–19. doi: 10.1016/j.arr.2017.08.001

Westerberg, G., Loureiro, A. I., Falcao, A., Nunes, T., Rocha, J. F., Fernandes-Ung, D., and Nagar, S. (2007). Variable sulfation of dietary polyphenols induced cytokine release and coagulation activation in humans. *Crit. Care Med.* 35, e199–e202. doi: 10.1097/CCM.0b013e3180219989

van der Meer, A. J., van der Made, S. M., Plat, J., and Mensink, R. P. (2015). Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. *PLoS One* 10, e0118393. doi: 10.1371/journal.pone.0118393

van der Meer, A. J., Scicluna, B. P., Moerland, P. D., Lin, J., Jacobson, E. W., Fan, Z., et al. (2011). Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson’s disease. *Neurosignals* 19, 163–174. doi: 10.1159/000328516

Yiu, E., Tai, G., Peverill, R., Lee, K., Croft, K., Mori, T., et al. (2013). An open label clinical pilot study of resveratrol as a treatment for Friedreich ataxia *(S43.006).* *Neurology* 80(7 Suppl.):S43.006.

Yoo, J., Kim, T. H., Fazleabas, A. T., Palomino, W. A., Ahn, S. H., Tayade, C., et al. (2017). KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progestosterone Resistance. *Sci. Rep.* 7:6765.

Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., 1, Schechtman, K., et al. (2012). Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. *Cell Metab.* 16, 658–664. doi: 10.1016/j.cmet.2012.09.015

You, W., Zheng, W., Weiss, S., Chua, K. F., and Steegborn, C. (2019). Structural basis for the activation and inhibition of Sirtuin 6 by quercetin and its derivatives. *Sci. Rep.* 9:19176. doi: 10.1038/s41598-019-55654-1

Yuan, H., and Marmorstein, R. (2012). Structural basis for sirtuin activity and inhibition. *J. Biol. Chem.* 287, 42348–42345. doi: 10.1074/jbc.R111.3272300

Zeng, Y., Nikitkova, A., Abdelsalam, H., Li, J., and Xiao, J. (2019). Activity of quercetin and kaemferol against Streplococcus mutans biofilm. *Arch Oral Biol.* 98, 9–16. doi: 10.1016/j.archoralbio.2018.11.005

Zhang, J. Y., Holbrook, M., Inagaki, E., Feng, B., Ko, D., Weisbrod, R., et al. (2017). The effects of resveratrol treatment on vascular function in type 2 diabetes mellitus. *Arterioscler. Thromb. Vasc. Biol.* 37:164. doi: 10.1161/ATV33.3164

Zhu, C. W., Grossman, H., Neugroschl, J., Parker, S., Burden, A., and Luo, X. Sano, M. (2018). A randomized, double-blind, placebo-controlled trial of resveratrol with glucose andmalate (RGm) to slow the progression of Alzheimer’s disease: a pilot study. *Alzheimers Dement.* 4, 609–616. doi: 10.1016/j.jalz.2018.09.009

Zocchi, L., and Sassone-Corsi, P. (2012). SIRT1-mediated deacytlation of MeCP2 and its potential conflict of interest. *Front. Psychiatry* 7:159. doi: 10.3389/fpsyt.2016.00159

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.